Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis
This real-world analysis investigated patients with follicular lymphoma in Italy receivingthree or more treatment lines (3L), focusing on therapeutic pathways with their rebounds onhealthcare resource consumptions and costs. Data were retrieved from administrative databases fromhealthcare entities covering about 13.3 million residents. Adults diagnosed with follicular lymphomawere identified between January 2015 and June 2020, and among… Leggi tutto »Burden of Illness in Follicular Lymphoma with Multiple Lines of Treatment, Italian RWE Analysis
The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy
Introduction: Chronic myeloid leukemia (CML) is a hematopoietic myeloproliferative disorder that accounts for 20% of all leukemias of adults. The introduction of tyrosine kinase inhibitors (TKIs) (imatinib, bosutinib, dasatinib, nilotinib, ponatinib) has yielded significant benefits for patients with CML in terms of survival and quality of life. This real-world analysis evaluated the economic burden for managing… Leggi tutto »The Economic Burden of Chronic Myeloid Leukemia in Patients with Later Lines: Findings from a Real-World Analysis in Italy